Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib
Puma Biotechnology
Exhibitor Puma Biotechnology 02-20 - Scripps CME Connection
Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
Puma Biotechnology Announces $10 Million Private Placement | Business Wire
Puma Biotechnology, Inc. | LinkedIn
Puma Biotech (PBYI) Stock up as Q2 Earnings & Sales Beat
PumaBiotech (@pumabiotech) / Twitter
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Puma Biotechnology
Takeda farms out cancer drug alisertib to Puma Biotech -
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in South Korea | Business Wire
Jobs with Puma Biotechnology
Puma Biotech Plunges on Sharp Drop in Cancer-Drug Sales - TheStreet
Puma Biotechnology
Puma Biotech plunges on drug side effects
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma Biotech shares slide after glimpse of trial data on cancer drug | Financial Times
Puma Biotech (PBYI) Stock up as Q2 Earnings & Sales Beat
Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer
Is Puma Biotechnology a Buy? | The Motley Fool
Puma Biotech Strikes Deal to Develop and Market its Breast Cancer Drug in China - Los Angeles Business Journal
SEC charges former Puma biotech exec with $1.1 million in insider trading
